A. Moliterni

发表

Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation.

G. Bonadonna, P. Valagussa, M. Zambetti, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer.

G. Bonadonna, R. Zucali, P. Valagussa, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Recurrence and mortality dynamics for breast cancer patients undergoing mastectomy according to estrogen receptor status: Different mortality but similar recurrence

Elia Biganzoli, Patrizia Boracchi, Danila Coradini, 2010, Cancer science.

Pilot study of primary chemotherapy with doxorubicin plus paclitaxel in women with locally advanced or operable breast cancer.

G. Grasselli, G. Bonadonna, M. Greco, 1997, Seminars in oncology.

Treatment of special breast cancer patients

M. Zambetti, A. Moliterni, 2006 .

Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study.

A. Marchianò, A. Fasolo, L. Gianni, 2006, Clinical breast cancer.

Long-term sequelae from adjuvant chemotherapy.

G. Bonadonna, P. Valagussa, M. Zambetti, 1993, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer.

S. Ménard, G. Bonadonna, S. Pilotti, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant chemotherapy after conservative surgery plus irradiation versus modified radical mastectomy. Analysis of drug dosing and toxicity.

G. Bonadonna, R. Weiss, P. Valagussa, 1987, The American journal of medicine.

Mitoxantrone as First-Salvage Chemotherapy in Relapsed Breast Cancer

G. Bonadonna, C. Brambilla, D. Codazzi, 1989, Tumori.

Comment to Anderson WF, Jatoi I, Devesa SS: Distinct Breast Cancer Incidence and Prognostic Patterns in the NCI’s SEER Program: Suggesting a Possible Link Between Etiology and Outcome. Breast Cancer Res Treat 90:127–137, 2005

R. Demicheli, G. Bonadonna, M. Greco, 2006, Breast Cancer Research and Treatment.

Vinorelbine: An active, non cross-resistant drug in advanced breast cancer. Results from a phase II study

R. Demicheli, A. Caraceni, G. Bonadonna, 2005, Breast Cancer Research and Treatment.

Adjuvant and neoadjuvant treatment of breast cancer with chemotherapy and/or endocrine therapy.

G. Bonadonna, C. Brambilla, L. Ferrari, 1991, Seminars in oncology.

S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2−positive locally recurrent/metastatic breast cancer (LR/mBC)

R. Greil, F. André, V. Semiglazov, 2011 .

30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study

G. Bonadonna, M. Daidone, S. Pilotti, 2005, BMJ : British Medical Journal.

Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process.

R. Demicheli, G. Bonadonna, R. Miceli, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.

J. Baselga, M. Climent, W. Eiermann, 2014, The Lancet. Oncology.

Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of ‘cures’

R. Demicheli, G. Bonadonna, C. Brambilla, 1999, Breast Cancer Research and Treatment.

Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer.

G. Bonadonna, L. Gianni, P. Valagussa, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up.

G. Bonadonna, C. Brambilla, P. Valagussa, 1995, The New England journal of medicine.

Single Institution trial of anthracycline‐ and taxane‐based chemotherapy for operable breast cancer: The ASTER study

L. Ferrari, S. Cresta, P. Valagussa, 2019, The breast journal.

Local recurrences following mastectomy: support for the concept of tumor dormancy.

R. Demicheli, G. Bonadonna, P. Valagussa, 1994, Journal of the National Cancer Institute.

HER2 O verexpression a nd D oxorubicin i n A djuvant Chemotherapy f or R esectable B reast C ancer

S. Ménard, G. Bonadonna, S. Pilotti, 2003 .

Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: A randomized clinical trial (INT09/98)

S. Ménard, M. Greco, M. Pierotti, 2014, Cancer.

p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy.

R. Demicheli, D. Coradini, M. Daidone, 2015, Breast.

Maspin influences response to doxorubicin by changing the tumor microenvironment organization

M. Carcangiu, E. Tagliabue, P. Casalini, 2014, International journal of cancer.

Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer.

G. Bonadonna, P. Valagussa, M. Zambetti, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant and neoadjuvant treatment of breast cancer.

G. Bonadonna, L. Gianni, P. Valagussa, 2001, Seminars in oncology.

Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute.

G. Bonadonna, C. Brambilla, L. Ferrari, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pain relief and sclerosis of bone metastases in a patient with breast cancer treated with tamoxifen, radiotherapy and pamidronate disodium: which treatment helped?

F. De Conno, F. Fulfaro, C. Ripamonti, 1998, Journal of Pain and Symptom Management.

Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes.

G. Bonadonna, L. Ferrari, P. Valagussa, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New adjuvant trials for resectable breast cancer at the Istituto Nazionale Tumori of Milan.

G. Bonadonna, U. Veronesi, P. Valagussa, 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Prospects for Doxorubicin in Adjuvant Breast Cancer Trials

G. Bonadonna, C. Brambilla, P. Valagussa, 1982 .

Activity of vinorelbine (VIN) in advanced breast cancer: Preliminary results of a phase II trial

R. Demicheli, A. Caraceni, G. Bonadonna, 1993 .

Vinorelbine: An active, non cross-resistant drug in advanced breast cancer. Results from a phase II study

R. Demicheli, A. Caraceni, G. Bonadonna, 2005, Breast Cancer Research and Treatment.